This week's tweet comes from Bruce Booth (@LifeSciVC), who points out analysts at Bernstein concluded that just six companies contributed to 77% of the increase in value of the biotech sector over the past three years.
There's no doubt that Amgen, Biogen Idec (NASDAQ:BIIB), Celgene (NASDAQ:CELG), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), and Alexion Pharmaceuticals (NASDAQ:ALXN) have seen substantial gains over the past couple of years, but as Fool contributor Brian Orelli and health-care bureau chief Max Macaluso point out in the following video, the large sizes of the companies is what causes the large contribution.
A smaller biotech that goes from a market cap of $500 million to $1 billion doesn't add much to the overall valuation of the industry, but the company still provides a 100% gain for investors.
The stat is more relevant for generalist investors who invest in biotech ETFs. Since the funds are tied to indexes dominated by the larger companies, their increased valuation will drive returns for the shares of the ETF.
Looking for growth outside the biotech sector?
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have found multibagger stocks time and again. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.
Brian Orelli has no position in any stocks mentioned. Max Macaluso owns shares of Celgene and Gilead Sciences. The Motley Fool recommends Celgene and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.